Impedimed Limited · ASX:IPD
Impedimed — Canaccord Drug and Device Conference 2025
16 slides from Impedimed's conference presentation, Oct 22, 2025
Slide 1: ImpediMed Limited - Canaccord Drug and Device Conference
For personal use only ImpediMed Limited Canaccord Drug and Device Conference Noosa Australia, October 2025 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 3: Agenda
Agenda For personal use only 1 Product Overview 2 Evolution and Strategy 3 Business Overview • Lymphoedema • Body Comp • Heart Failure 4 H1 FY26 Outlook Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 3
Slide 4: ImpediMed's BIS Technology
ImpediMed’s BIS Technology SOZO using Bioimpedance Spectroscopy (BIS) Non-invasively, quickly and accurately measures, monitors and manages fluid status and tissue composition For personal use only Bioimpedance Spectroscopy (BIS) Low Frequency Current passes around cells Fluid 256 frequencies Fat Hi
Slide 5: SOZO Digital Health Platform
SOZO Digital Health Platform SOZO measures and tracks critical patient data For personal use only • L-Dex® lymphoedema index • HF-DexTM heart failure index • Total body water • Protein and minerals • Extracellular fluid • Basal metabolic rate • Intracellular fluid • Phase angle • Skeletal muscle mas
Slide 6: ImpediMed: Strategy set and Execution now the focus
ImpediMed: Strategy set and Execution now the focus ❑ Board and Executive in place: Australian based globally experienced team For personal use only • Pfizer IBM Google Resmed Polynovo Nanosonics ❑ Product developed: U400 SOZO® SOZO Pro • Lie down 20-minute test transformed to a stand up 30 second t
Slide 7: Financial metrics continue to trend positively
Financial metrics continue to trend positively Q4 FY25 Financial Summary For personal use only • Record TCV $6.3m. • Revenue $3.3m. • Annual recurring revenue $14.0m. • Quarterly operating cash outflow ($3.5m). • Cash balance $22.2m, equating to 6.3 quarters of operating cash flow. • FY25 cash cost
Slide 8: Strategy
Strategy Achieve profitability through a focus on sales, marketing and clinical execution For personal use only Current priorities Achieve profitability Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class customer Financial discipline Body Comp Develop new markets growth ex
Slide 9: Improving Survivorship for Breast Cancer Patients
Improving Survivorship for Breast Cancer Patients 310k 1 in 5 For personal use only Newly diagnosed US breast Breast cancer patients will cancer patients every year1 develop lymphedema2 resulting in • There are 4+ million breast • Isolation and depression3 cancer survivors1 • Hospitalisation risk4 •
Slide 10: SOZO is replacing time consuming & outdated current standard of care
SOZO is replacing time consuming & outdated current standard of care Early, objective & fast detection of Breast Cancer Related Lymphoedema Bioimpedance Spectroscopy (BIS) – FDA-cleared, Clinically Validated, For personal use only Current Standard of Care Subjective or Time-Consuming Guideline Suppo
Slide 11: Lymphoedema: Sustainable sales growth expected in FY26
Lymphoedema: Sustainable sales growth expected in FY26 Confident in delivering sustainable sales growth in FY26 For personal use only • Solid foundation set in the US - ARR business model with over 600 devices in leading US healthcare customers • SOZO currently utilised in 18 of the top 25 US hospit
Slide 12: Body Comp: Measured expansion initiated
Body Comp: Measured expansion initiated SOZO is the only bioimpedance device with US FDA clearance to measure Body Comp in an unhealthy patient population For personal use only Body Comp opportunity growing with the use of GLP-1 drugs Recently changed clinical guidelines recommend bioimpedance • Com
Slide 13: Heart Failure: Expansion initiated
Heart Failure: Expansion initiated Heart Failure opportunity For personal use only • In the US, there are currently 6.7M HF patients, expected to grow to 8.5M patients by 2030 1. • US outpatient heart failure fluid monitoring TAM estimated at $1.1bn, based on a 30% share of the reimbursed market. •
Slide 14: Outlook for H1 FY26
Outlook for H1 FY26 ❑ Grow US sales leveraging changes to sales team and expanded reimbursement For personal use only o Continue to initiate Lymphoedema awareness activities to generate leads o Further measured investment to accelerate sales strategy o Drive improvement in sales metrics o Fill remai
Slide 15: The Value Proposition
The Value Proposition Multiple Regulatory Clearances Lymphoedema For personal use only Heart Failure Reimbursement Renal Failure 87% of US Body Comp Successful Insured Lives Global RCT covered Lymphoedema >80% coverage prevention in 41 US States Guideline and BCRL TAM Standard $600M Inclusion Multi-
Slide 16: For personal use only
impedimed’ Ajuo asn jeuosiad 4104 16
ImpediMed — Canaccord Drug and Device Conference 2025 on 6ix